Why Structure Therapeutics (GPCR) Is Back on Investors’ Radar

Structure Therapeutics (GPCR) is drawing fresh attention after recent analyst commentary pointed to growing confidence in its obesity pipeline, including key trial progress for aleniglipron and a new licensing deal with Genentech.

The agreement with Genentech includes a US$100 million upfront payment and potential royalties, while analysts are watching upcoming clinical milestones such as the 44 week ACCESS II readout and a planned Phase 3 start in 2026.

The recent analyst optimism and Genentech deal have arrived alongside sharp share price momentum, with a 7 day share price return of 16.81% and a 90 day share price return of 241.41%. The 1 year total shareholder return of 221.17% points to strong longer term gains.

If this kind of rerating in obesity drug developers has your attention, it could be a good moment to see what else is moving across healthcare stocks.

With the stock at US$91.02 and the average analyst target at US$105.13, plus a recent target hike to US$140, you have to ask: is there still upside left here, or is the market already pricing in the obesity pipeline?

Price to Book of 8.2x: Is It Justified?

At a last close of US$91.02, Structure Therapeutics is trading on a P/B of 8.2x, which screens as good value against its direct peers but expensive versus the broader US pharmaceuticals group.

The P/B ratio compares the market value of the company to its book value, so it is often used for early stage or unprofitable businesses where earnings based multiples are less meaningful. For a clinical stage biopharma name with no meaningful revenue and a reported net loss of US$210.69m, investors are effectively paying for the asset base and future pipeline rather than current profits.

Compared with its immediate peer set, GPCR looks inexpensive, with its 8.2x P/B sitting well below the peer average of 41.8x. This suggests the market is attaching a lower relative valuation to its balance sheet and pipeline than to some comparable names. Against the wider US pharmaceuticals industry, that same 8.2x multiple is materially higher than the 2.6x industry average. Anyone looking at the stock through this lens is weighing a discount to high growth peers against a sizable premium to the sector at large.

Result: Price to book of 8.2x (ABOUT RIGHT)

However, the story still leans heavily on successful obesity trial outcomes and partner execution, so any clinical setbacks or deal changes could quickly hit sentiment.

Build Your Own Structure Therapeutics Narrative

If you look at the numbers and reach a different conclusion, or prefer to test your own assumptions, you can build a personalised view in a few minutes with Do it your way.

A great starting point for your Structure Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Ready for more stock ideas worth your time?

If Structure Therapeutics has you thinking harder about where the next opportunity might come from, do not stop here. Broaden your watchlist with focused screeners.

• Spot early stage names that meet clear financial filters by checking out these 3532 penny stocks with strong financials that already pass basic strength checks.
• Ride the next wave of tech by scanning these 23 AI penny stocks for companies tied to artificial intelligence themes that interest you most.
• Hunt for potential mispricing by reviewing these 877 undervalued stocks based on cash flows that current cash flow metrics suggest may trade below their calculated value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.